761 related articles for article (PubMed ID: 18836486)
21. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.
Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D
Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401
[TBL] [Abstract][Full Text] [Related]
22. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W
Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
24. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.
Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A
J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338
[TBL] [Abstract][Full Text] [Related]
25. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
26. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
27. Enhanced tumorigenesis and lymphatic metastasis of CD133+ hepatocarcinoma ascites syngeneic cell lines mediated by JNK signaling pathway in vitro and in vivo.
Jin Y; Mao J; Wang H; Hou Z; Ma W; Zhang J; Wang B; Huang Y; Zang S; Tang J; Li L
Biomed Pharmacother; 2013 May; 67(4):337-45. PubMed ID: 23582787
[TBL] [Abstract][Full Text] [Related]
28. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma.
Yang JP; Liu Y; Zhong W; Yu D; Wen LJ; Jin CS
Chin Med J (Engl); 2011 Apr; 124(7):1055-60. PubMed ID: 21542968
[TBL] [Abstract][Full Text] [Related]
29. Biological and genetic characteristics of tumor-initiating cells in colon cancer.
Ieta K; Tanaka F; Haraguchi N; Kita Y; Sakashita H; Mimori K; Matsumoto T; Inoue H; Kuwano H; Mori M
Ann Surg Oncol; 2008 Feb; 15(2):638-48. PubMed ID: 17932721
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
Gallmeier E; Hermann PC; Mueller MT; Machado JG; Ziesch A; De Toni EN; Palagyi A; Eisen C; Ellwart JW; Rivera J; Rubio-Viqueira B; Hidalgo M; Bunz F; Göke B; Heeschen C
Stem Cells; 2011 Mar; 29(3):418-29. PubMed ID: 21308861
[TBL] [Abstract][Full Text] [Related]
31. Bmi-1 is essential for the oncogenic potential in CD133(+) human laryngeal cancer cells.
Wei X; He J; Wang J; Yang X; Ma B
Tumour Biol; 2015 Nov; 36(11):8931-42. PubMed ID: 26081615
[TBL] [Abstract][Full Text] [Related]
32. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of CD133(+) human colon cancer SW620 cells.
Kawamoto H; Yuasa T; Kubota Y; Seita M; Sasamoto H; Shahid JM; Hayashi T; Nakahara H; Hassan R; Iwamuro M; Kondo E; Nakaji S; Tanaka N; Kobayashi N
Cell Transplant; 2010; 19(6):857-64. PubMed ID: 20587144
[TBL] [Abstract][Full Text] [Related]
34. SNAI1 overexpression induces stemness and promotes ovarian cancer cell invasion and metastasis.
Lu ZY; Dong R; Li D; Li WB; Xu FQ; Geng Y; Zhang YS
Oncol Rep; 2012 May; 27(5):1587-91. PubMed ID: 22344746
[TBL] [Abstract][Full Text] [Related]
35. Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM- Lung Cancer-Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis.
Bertolini G; D'Amico L; Moro M; Landoni E; Perego P; Miceli R; Gatti L; Andriani F; Wong D; Caserini R; Tortoreto M; Milione M; Ferracini R; Mariani L; Pastorino U; Roato I; Sozzi G; Roz L
Cancer Res; 2015 Sep; 75(17):3636-49. PubMed ID: 26141860
[TBL] [Abstract][Full Text] [Related]
36. CD133 is a marker of bioenergetic stress in human glioma.
Griguer CE; Oliva CR; Gobin E; Marcorelles P; Benos DJ; Lancaster JR; Gillespie GY
PLoS One; 2008; 3(11):e3655. PubMed ID: 18985161
[TBL] [Abstract][Full Text] [Related]
37. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
38. Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines.
Schiapparelli P; Enguita-Germán M; Balbuena J; Rey JA; Lázcoz P; Castresana JS
Oncol Rep; 2010 Nov; 24(5):1355-62. PubMed ID: 20878131
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of cancer stem cells in ovarian yolk sac tumors.
Suzuki S; Terauchi M; Umezu T; Kajiyama H; Shibata K; Nawa A; Kikkawa F
Cancer Sci; 2010 Oct; 101(10):2179-85. PubMed ID: 20804503
[TBL] [Abstract][Full Text] [Related]
40. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
Sarvi S; Mackinnon AC; Avlonitis N; Bradley M; Rintoul RC; Rassl DM; Wang W; Forbes SJ; Gregory CD; Sethi T
Cancer Res; 2014 Mar; 74(5):1554-65. PubMed ID: 24436149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
